Neurodegeneration: An expansion in ALS genetics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Conserved components of the macroautophagy machinery in Caenorhabditis elegans.Genetics · 2025
   Review
2. Repeats expansions inIBRO neuroscience reports · 2021
   Article
3. MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2018
   Review
4. Modeling ALS and FTD with iPSC-derived neurons.Brain research · 2017
   Review
5. The Neurotoxic TAUMolecular medicine (Cambridge, Mass.) · 2016
   Article
6. How Common Is Disorder? Occurrence of Disordered Residues in Four Domains of Life.International journal of molecular sciences · 2015
   Article
7. The axis of progression of disease.Cancer informatics · 2014
   Article
8. Early presymptomatic cholinergic dysfunction in a murine model of amyotrophic lateral sclerosis.Brain and behavior · 2013
   Article
9. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.Nature genetics · 2012
   Article
10. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.Acta neuropathologica · 2012
    Article
11. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
12. ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice.PLoS genetics · 2012
    Article
13. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.Nature reviews. Neuroscience · 2011
    Review
14. [Motor neuron diseases].Der Nervenarzt · 2011
    Article
15. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.Human molecular genetics · 2011
    Article
16. RNA-binding proteins with prion-like domains in ALS and FTLD-U.Prion
    Review

Corrections and comments

• Comment on
  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as